Treating Paediatric Patients
IQoro’s new unique neuromuscular treatment method also works on children and adolescents. Clinicians working with children may find IQoro helpful with reflux problems, dysphagia and developmental issues related to the neurodevelopment of the swallow, physical orofacial development, and others.
Treating paediatric patients with congenital conditions
In some countries, notably Sweden, IQoro treatment is used in children and young people with congenital conditions including those with cleft palate, Cerebral Palsy, Down’s syndrome; and those with acquired brain injuries, and more. In the UK some Speech and Language Therapists have started similar work.
IQoro treatment can promote normal orofacial development including addressing a propensity to an under- or over-bite, unnatural palate arch formation and more. IQoro is effective at promoting the neurological development of the swallow.
Use the paediatric model for children up to 10 years
Reflux and dysphagia conditions may be addressed with IQoro at any stage after the stomach has assumed a normal position below the diaphragm; typically this is after 12 – 18 months. Children of this age, and up to about 10 years old, should be treated using the ‘child’ size of IQoro as listed on the DTA drug tariff.
Evidence on treating paediatric patients with IQoro
A specific set of UK case studies evidencing positive outcomes of IQoro treatment in children and young people with Cerebral Palsy – especially in addressing saliva control dysfunction.
To learn more about IQoro treatment use in paediatrics, read about about dysphagia in children. The sections relating to HCP care of dysphagia, and HCP care of acid reflux are also highly relevant.